What it's for (Indications)
- Ivabradine is a highly selective inhibitor of the If current, indicated for the treatment of stable, symptomatic chronic heart failure with reduced ejection fraction (HFrEF) in adult patients who are in sinus rhythm with a resting heart rate of at least 70 beats per minute (bpm).
- It is specifically used in patients who are either on a maximally tolerated dose of beta-blockers, or have a contraindication to beta-blocker use.
- The primary goal of ivabradine therapy in this patient population is to reduce the risk of hospitalization for worsening heart failure, thereby improving patient outcomes and quality of life.
- Its use is predicated on careful patient selection, ensuring patients meet the specified heart rate and rhythm criteria to maximize benefit and minimize risks associated with heart rate reduction.
- The clinical evidence supports its role as an add-on therapy or an alternative for those intolerant to conventional treatments in specific heart failure phenotypes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended starting dose of ivabradine is 5 mg orally twice daily, taken with meals. For patients aged 75 years and older, a lower initial dose of 2.5 mg twice daily should be considered due to potential increased sensitivity and altered pharmacokinetics. After two weeks of treatment, the dosage should be adjusted based on the patient's resting heart rate response and clinical tolerance. The target resting heart rate range is typically between 50 and 60 bpm. If the resting heart rate remains above 60 bpm, the dose may be increased to a maximum of 7.5 mg twice daily. Conversely, if the resting heart rate falls below 50 bpm or if the patient experiences signs or symptoms of bradycardia (e.g., dizziness, fatigue, syncope), the dose should be reduced. If the heart rate remains persistently below 50 bpm or if symptomatic bradycardia persists despite dose reduction, ivabradine should be discontinued. Close monitoring of heart rate and rhythm is crucial throughout therapy. |
Safety & Warnings
Common Side Effects
- Common side effects associated with ivabradine therapy predominantly relate to its mechanism of action on heart rate and visual perception.
- The most frequently reported adverse event is luminous phenomena (phosphenes), often described as transient enhanced brightness in a limited area of the visual field, halos, or decomposed images.
- These visual disturbances are typically mild to moderate in intensity, usually occur during the first two months of treatment, and often resolve during continued treatment or upon discontinuation.
- Bradycardia is another very common side effect, which can lead to symptoms such as dizziness, fatigue, and syncope; careful dose titration and monitoring are essential.
- Other reported side effects include atrial fibrillation, headache, first-degree atrioventricular block, ventricular extrasystoles, blurred vision, and hypertension.
- Rarely, angioedema has been reported.
- Patients should be counseled on these potential effects and instructed to report any new or worsening symptoms to their healthcare provider promptly.
Serious Warnings
- Black Box Warning: Ivabradine (e.g., Ivatab) does not carry a formal FDA Black Box Warning. However, it is associated with several serious warnings that healthcare professionals and patients must be aware of to ensure safe and effective use. **Serious Warnings: 1. **Embryo-Fetal Toxicity:** Ivabradine can cause fetal harm when administered to a pregnant woman. Animal studies have shown embryolethality and teratogenicity at clinically relevant exposures. Therefore, pregnant women should not take ivabradine, and women of childbearing potential must use effective contraception during treatment with ivabradine. Healthcare providers should counsel patients on these risks. 2. **Risk of Atrial Fibrillation:** Treatment with ivabradine increases the risk of atrial fibrillation. Patients should be monitored regularly for signs and symptoms of atrial fibrillation (e.g., palpitations, fatigue, dyspnea). If atrial fibrillation develops during treatment, ivabradine should be discontinued immediately. 3. **Bradycardia:** Ivabradine causes a dose-dependent reduction in heart rate and can lead to severe symptomatic bradycardia (e.g., dizziness, fatigue, syncope). It is contraindicated in patients with a resting heart rate below 60 beats per minute prior to treatment and in those with symptomatic bradycardia. The dose should be adjusted based on the patient's heart rate response, aiming for a resting heart rate between 50 and 60 bpm. If severe symptomatic bradycardia or a persistent heart rate below 50 bpm occurs, ivabradine must be discontinued. 4. **Not for Acute Decompensated Heart Failure:** Ivabradine is not indicated for, and should not be used in, patients with acute decompensated heart failure. Its safety and efficacy have not been established in this setting, and its use could potentially worsen the patient's condition. 5. **Concomitant Use with Strong CYP3A4 Inhibitors:** Concomitant use of ivabradine with strong cytochrome P450 3A4 (CYP3A4) inhibitors is contraindicated. Such co-administration significantly increases ivabradine plasma concentrations, which can lead to severe bradycardia and associated complications. Examples of strong CYP3A4 inhibitors include ketoconazole, itraconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and nelfinavir. Patients should be thoroughly screened for concomitant medications before initiating ivabradine.
- Ivabradine is not indicated for patients with acute decompensated heart failure, as its safety and efficacy have not been established in this emergent setting.
- It is crucial to assess a patient's resting heart rate and rhythm prior to initiating therapy, and ivabradine should not be started if the heart rate is below 60 bpm or if the patient presents with symptomatic bradycardia.
- The drug significantly increases the risk of atrial fibrillation, and patients should be regularly monitored for symptoms suggestive of this arrhythmia; if atrial fibrillation develops, ivabradine should be discontinued.
- Patients with severe hepatic impairment or those taking strong cytochrome P450 3A4 (CYP3A4) inhibitors are at increased risk of elevated ivabradine plasma concentrations and subsequent severe bradycardia, thus requiring contraindication for these groups.
- Furthermore, caution is advised in patients with moderate hepatic impairment or moderate CYP3A4 inhibitors.
- Due to potential embryo-fetal toxicity, women of childbearing potential must use effective contraception during ivabradine treatment.
- The visual disturbances, while often transient, may impact the ability to drive or operate machinery, particularly at night, and patients should be advised accordingly.
How it Works (Mechanism of Action)
Ivabradine exerts its therapeutic effects by selectively and specifically inhibiting the cardiac pacemaker If current (also known as the 'funny' current), which flows through hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the sinoatrial node. This current is responsible for the spontaneous diastolic depolarization of the sinoatrial node pacemaker cells, a critical determinant of heart rate. By blocking the If current, ivabradine slows the rate of depolarization, thereby decreasing the heart rate in a dose-dependent manner. This reduction in heart rate is achieved without affecting myocardial contractility, ventricular repolarization, or intra-atrial, atrioventricular, or intra-ventricular conduction times. The heart rate-lowering effect is unique in that it directly targets the pacemaker activity, leading to a reduction in cardiac workload, improved diastolic filling time, and potentially enhanced myocardial oxygen supply and demand balance, which is beneficial in stable heart failure with reduced ejection fraction.